Dehito, Julieta L.

HRN: 18-65-67  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/29/2024
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
02/29/2024
03/07/2024
IV
1.5 G
Q8
Abscess
Waiting Final Action 
02/29/2024
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
02/29/2024
03/07/2024
IV
1.5 G
Q8
Abscess
Waiting Final Action 
02/29/2024
CLINDAMYCIN 150MG/ML, 4ML (AMP)
02/29/2024
03/12/2024
IV
600
Q8
Abscess
Waiting Final Action 
03/01/2024
CEFTAZIDIME 1GM (VIAL)
03/01/2024
03/13/2024
IV
2 Grams
Every 8 Hours
Abscess, Left Lateral Neck Mass; DM Type 2 Uncontrolled
Waiting Final Action 
03/06/2024
CEFTAZIDIME 1GM (VIAL)
03/06/2024
03/10/2024
IV
2gm
Every 8 Hours
Abscess, Left Lateral Neck Mass; DM Type 2 Uncontrolled
Waiting Final Action 
03/08/2024
MUPIROCIN 2%, 15G (TUBE)
03/08/2024
03/15/2024
TOPICAL
Apply Generously
BID
Neck Abscess
Waiting Final Action 
03/09/2024
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
03/09/2024
03/16/2024
IV
4.5 Grams
Every 8 Hours
Abscess, Left Lateral Neck Mass; DM Type 2 Uncontrolled
Waiting Final Action 
03/11/2024
RIFAXIMIN 200MG (TAB)
03/11/2024
03/18/2024
PO
200
BID
Hepatic Encephalitis
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: